Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma

Next Previous
Trial Profile

A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD-4573 (Primary)
  • Indications Hodgkin's disease; Large granular lymphocytic leukaemia; Mycosis fungoides; Peripheral T-cell lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; Primary cutaneous anaplastic large cell lymphoma; Sezary syndrome; T-cell lymphoma; T-cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 04 Mar 2024 Status changed from active, no longer recruiting to completed.
  • 30 Nov 2023 Some new indications have been added, namely- Large-granular-lymphocytic-leukaemia, Mycosis-fungoides, Sezary-syndrome, Primary-cutaneous-anaplastic-large-cell-lymphoma, Precursor-T-cell-lymphoblastic-leukaemia-lymphoma and T-cell-prolymphocytic-leukaemia.
  • 30 Nov 2023 Planned End Date changed from 25 Aug 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top